Table 4.
TNFα Regulated Genes Differentially Expressed in the Amygdala of Blast-Exposed Animals between 6 Weeks and 12 Months Post-Blast
| Gene | Prediction | Log2FC | Finding |
|---|---|---|---|
| Pnpla1 | Activated | 2.58 | Increased |
| Hsp8 | Inhibited | 1.02 | Increaseda |
| Hla-a | Activated | 0.87 | Increased |
| Lrg1 | Activated | 0.83 | Increased |
| P3h2 | Activated | 0.77 | Increased |
| Isg15 | Activated | 0.73 | Increased |
| Fcgr2b | Activated | 0.70 | Increased |
| C4a/C4b | Activated | 0.61 | Increased |
| Ass1 | Activated | 0.53 | Increased |
| Gpr84 | Activated | 0.52 | Increased |
| Ncf1 | Activated | 0.52 | Increased |
| Cebpb | Activated | 0.50 | Increased |
| Ilra | Activated | 0.45 | Increased |
| Srebf1 | Inhibited | 0.42 | Increaseda |
| Jund | Inhibited | 0.38 | Increaseda |
| Lfng | Inhibited | 0.37 | Increaseda |
| Chst2 | Activated | 0.35 | Increased |
| Ctss | Activated | 0.33 | Increased |
| Ech1 | Inhibited | 0.32 | Increaseda |
| Pcsk6 | Inhibited | 0.29 | Increaseda |
| Pc | Inhibited | 0.25 | Increaseda |
| Rps3 | Activated | 0.25 | Increased |
| Ctsb | Activated | 0.23 | Increased |
| Phb | Inhibited | 0.20 | Increaseda |
| Sqstm1 | Activated | 0.16 | Increased |
| Magi1 | Inhibited | -0.25 | Decreaseda |
| Sorbs1 | Activated | -0.28 | Decreased |
| Hapln1 | Activated | -0.29 | Decreased |
| Celf1 | Inhibited | -0.29 | Decreaseda |
| Apc | Activated | -0.29 | Decreased |
| Tfpi | Activated | -0.29 | Decreased |
| Ccnd2 | Activated | -0.37 | Decreased |
| Gsk3b | Activated | -0.39 | Decreased |
| Cers4 | Activated | -0.39 | Decreased |
| Slc1a2 | Activated | -0.39 | Decreased |
| Tfrc | Activated | -0.39 | Decreased |
| Ccr5 | Activated | -0.73 | Decreased |
| Lxn | Activated | -0.49 | Decreased |
| Cyp11b | Activated | -1.28 | Decreased |
| Hprt1 | Inhibited | -4.43 | Decreaseda |
Gene direction change not consistent with TNFα activation.
TNF, tumor necrosis factor; FC, fold change; Pnpla1, patatin like phospholipase domain containing 1; Hsp 8, heat shock 70 kDa protein 8; Hla-a, human leukocyte antigen; Lrg1, leucine-rich α-2 glycoprotein 1; P3h2, prolyl 3-hydroxylase 2; Isg1, interferon-stimulated gene 15; Fcgr2b, Fc Gamma Receptor IIb; C4, complement component; Ass1, argininosuccinate synthase 1; Gpr 84, G protein-coupled receptor 84; Ncf1, neutrophil cytosolic factor 1; Cebpb, Ccaat enhancer binding protein beta; Ilra, interleukin 7 receptor; Srebf1, Sterol regulatory element-binding transcription factor 1; Jund, Jund proto-oncogene; Lfng O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase; Chst2, carbohydrate sulfotransferase 2; Cs, cathepsin S; Ech1, enoyl-CoA hydratase 1; Pcsk6, proprotein convertase subtilisin/kexin type 6; Pc, pyruvate carboxylase; Rps 3, ribosomal protein S3; Ctsb, cathepsin B; Phb, prohibitin; Sqstm1, sequestosome 1; Magi1, membrane associated guanylate kinase; Sorbs1, sorbin and Sh3 domain containing 1; Hpln1, hyaluronan and proteoglycan link protein; Celf1, Cugbp elav-like family member 1; Apc, adenomatous polyposis coli; Tfpi, tissue factor pathway inhibitor; Ccnd2, cyclin D2; Gsk3b, glycogen synthase kinase-3 beta; Cers4, ceramide synthase 4; Slc1a2, solute carrier family 1 member 2; Tfrc, transferrin receptor; Ccr5, C-C chemokine receptor 5; Lxn, latexin; Cyp11b, cytochrome P450 family 11 subfamily B member 1; Hprt1, hypoxanthine phosphoribosyltransferase 1.